ReviewFrontiers in chemistry2025
Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.
Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoporous silica nanoparticles (MSNs) offer remarkable opportunities for the loading and delivery of drugs and other small molecules due to their large specific surface area, tunable mesoporous pore size, ease of modification, and excellent biocompatibility. The active silica hydroxyl groups (Si-OH) on the surface provide a good basis for a variety of modification and functionalization strategies, and thus MSNs show great potential in drug delivery systems, especially in studies involving the loading, transport, and release of anticancer drugs, particularly in the field of oncology therapeutics. The current review highlights MSNs as promising platforms for breast cancer therapy, with a special focus on the diverse applications of MSNs in breast cancer therapy, which are related to a wide range of applications with different structures and designs, functionalization strategies, prevalent synthesis methods, and potential clinical uses. Afterwards, we review targeted MSNs for enhancing precision medicine and therapeutic efficacy, and then focus on specific applications of MSNs in breast cancer therapy and various stimulus-responsive surface modifications, with specific applications including drug delivery, photodynamic therapy, photothermal therapy, combined therapeutic approaches, gene therapy, and immunotherapy. In addition, the challenges of MSNs in breast cancer and their future prospects are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.